Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma

Bone

Volumn 50, Issue 1, 2012, Pages 171-181

  Thayanithy, Venugopal ^a   Sarver, Aaron L ^b   Kartha, Reena V ^c   Li, Lihua ^a   Angstadt, Andrea Y ^d   Breen, Matthew ^d   Steer, Clifford J ^b,e,f   Modiano, Jaime F ^b,f   Subramanian, Subbaya ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

14q32 miRNAs; Bone neoplasm; CMYC; MiR 17 92; Osteosarcoma

Indexed keywords

COMPLEMENTARY DNA; MICRORNA; MICRORNA 134; MICRORNA 17 92; MICRORNA 369 3P; MICRORNA 382; MICRORNA 544; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; BONE TISSUE; CHROMOSOME 14Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; GENE DELETION; GENE DOSAGE; GENE INTERACTION; GENE LOCUS; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ONCOGENE C MYC; OSTEOSARCOMA; PREDICTION; RNA TRANSCRIPTION;

ADOLESCENT; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; CHROMOSOMES, HUMAN, PAIR 14; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; MULTIGENE FAMILY; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 80755184684     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.10.012     Document Type: Article

References (47)

1. Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007, 26:1-18.
2. Marulanda G.A., Henderson E.R., Johnson D.A., Letson G.D., Cheong D. Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control 2008, 15:13-20.
3. van Dartel M., Cornelissen P.W., Redeker S., Tarkkanen M., Knuutila S., Hogendoorn P.C., et al. Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genet Cytogenet 2002, 139:91-96.
4. Lu X.Y., Lu Y., Zhao Y.J., Jaeweon K., Kang J., Xiao-Nan L., et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 2008, 6:937-946.
5. Ueda T., Healey J.H., Huvos A.G., Ladanyi M. Amplification of the MYC gene in osteosarcoma secondary to Paget's disease of bone. Sarcoma 1997, 1:131-134.
6. Bogenmann E., Moghadam H., DeClerck Y.A., Mock A. c-myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res 1987, 47:3808-3814.
7. Ikeda S., Sumii H., Akiyama K., Watanabe S., Ito S., Inoue H., et al. Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 1989, 80:6-9.
8. Cleton-Jansen A.M., Anninga J.K., Briaire-de Bruijn I.H., Romeo S., Oosting J., Egeler R.M., et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 2009, 101:1909-1918.
9. Cole M.D., McMahon S.B. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999, 18:2916-2924.
10. Berman S.D., Calo E., Landman A.S., Danielian P.S., Miller E.S., West J.C., et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A 2008, 105:11851-11856.
11. Feugeas O., Guriec N., Babin-Boilletot A., Marcellin L., Simon P., Babin S., et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 1996, 14:467-472.
12. Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 204:138-46.
13. Osaki M., Takeshita F., Sugimoto Y., Kosaka N., Yamamoto Y., Yoshioka Y., et al. MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression. Mol Ther 2011, 19:1123-1130.
14. Ziyan W., Shuhua Y., Xiufang W., Xiaoyun L. MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol 2010, doi:10.1007/s12032-010-9563-7.
15. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
16. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends Mol Med 2006, 12:580-587.
17. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
18. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
19. Lee Y.S., Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009, 4:199-227.
20. Inose H., Ochi H., Kimura A., Fujita K., Xu R., Sato S., et al. A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci U S A 2009, 106:20794-20799.
21. Li H., Xie H., Liu W., Hu R., Huang B., Tan Y.F., et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 2009, 119:3666-3677.
22. Fan J.B., Yeakley J.M., Bibikova M., Chudin E., Wickham E., Chen J., et al. A versatile assay for high-throughput gene expression profiling on universal array matrices. Genom Res 2004, 14:878-885.
23. Sarver A.L. Toward understanding the informatics and statistical aspects of micro-RNA profiling. J Cardiovasc Transl Res 2010, 3:204-211.
24. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
25. Riccardi C., Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006, 1:1458-1461.
26. Harris S.A., Tau K.R., Enger R.J., Toft D.O., Riggs B.L., Spelsberg T.C. Estrogen response in the hFOB 1.19 human fetal osteoblastic cell line stably transfected with the human estrogen receptor gene. J Cell Biochem 1995, 59:193-201.
27. Sudo H., Kodama H.A., Amagai Y., Yamamoto S., Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 1983, 96:191-198.
28. Sarver A.L., Phalak R., Thayanithy V., Subramanian S. S-MED: sarcoma microRNA expression database. Lab Invest 2010, 90:753-761.
29. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
30. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
31. Gamberi G., Benassi M.S., Bohling T., Ragazzini P., Molendini L., Sollazzo M.R., et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 1998, 55:556-563.
32. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008, 36:D154-D158.
33. Miranda K.C., Huynh T., Tay Y., Ang Y.S., Tam W.L., Thomson A.M., et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217.
34. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009, 106:3207-3212.
35. Song B., Wang Y., Xi Y., Kudo K., Bruheim S., Botchkina G.I., et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28:4065-4074.
36. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, Mabuchi Y, et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 29:5687-99.
37. Gallant P. Myc, cell competition, and compensatory proliferation. Cancer Res 2005, 65:6485-6487.
38. Johnston L.A., Gallant P. Control of growth and organ size in Drosophila. Bioessays 2002, 24:54-64.
39. Hashiramoto A., Sano H., Maekawa T., Kawahito Y., Kimura S., Kusaka Y., et al. C-myc antisense oligodeoxynucleotides can induce apoptosis and down-regulate Fas expression in rheumatoid synoviocytes. Arthritis Rheum 1999, 42:954-962.
40. Russo P., Arzani D., Trombino S., Falugi C. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor. J Pharmacol Exp Ther 2003, 304:37-47.
41. D'Agnano I., Valentini A., Fornari C., Bucci B., Starace G., Felsani A., et al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels. Oncogene 2001, 20:2814-2825.
42. Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008, 133:217-222.
43. Seitz H., Royo H., Bortolin M.L., Lin S.P., Ferguson-Smith A.C., Cavaille J. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 2004, 14:1741-1748.
44. Takahashi N., Okamoto A., Kobayashi R., Shirai M., Obata Y., Ogawa H., et al. Deletion of Gtl2, imprinted non-coding RNA, with its differentially methylated region induces lethal parent-origin-dependent defects in mice. Hum Mol Genet 2009, 18:1879-1888.
45. Hagan J.P., O'Neill B.L., Stewart C.L., Kozlov S.V., Croce C.M. At least ten genes define the imprinted Dlk1-Dio3 cluster on mouse chromosome 12qF1. PLoS One 2009, 4:e4352.
46. Kagami M., Sekita Y., Nishimura G., Irie M., Kato F., Okada M., et al. Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes. Nat Genet 2008, 40:237-242.
47. Zhou Y., Zhong Y., Wang Y., Zhang X., Batista D.L., Gejman R., et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem 2007, 282:24731-24742.